Chardan Capital restated their buy rating on shares of Oculis (NASDAQ:OCS - Free Report) in a research note published on Tuesday morning,Benzinga reports. The firm currently has a $28.00 target price on the stock.
Separately, HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Oculis in a research report on Monday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Oculis presently has an average rating of "Buy" and a consensus price target of $28.80.
Read Our Latest Research Report on OCS
Oculis Stock Performance
OCS stock traded up $0.57 during midday trading on Tuesday, reaching $18.22. 153,868 shares of the company's stock traded hands, compared to its average volume of 122,917. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $10.50 and a 52-week high of $18.40. The stock has a market cap of $737.98 million, a P/E ratio of -9.44 and a beta of -0.33. The stock's 50-day moving average is $16.35 and its 200 day moving average is $13.84.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
